Author

K. Van Bocxlaer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Assay:scRNA-seq· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

H. Ashwin· 2 shared P. Kaye· 2 shared A. F. Francisco· 1 shared A. L. Gonzalez-Munoz· 1 shared A. Layton· 1 shared A. M. Sandercock· 1 shared A. Tiberghien· 1 shared B. Vojtkova· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Ashwin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

UVB modifies skin immune-stroma cross-talk and promotes effector T cell recruitment during cryptic Leishmania donovani infection

M. Montes de Oca, S. Dey, K. Van Bocxlaer, H. Ashwin, N. Brown, E. Myburgh, N. S. Dey, G. F. Rani, E. Muscutt, M. Osman, D. Perez-Mazliah, S. James, L. Gilbert, M. Chatterjee, P. Kaye

This study uses scRNA-seq and spatial transcriptomics to show UVB exposure alters immune-stromal interactions and T cell recruitment during cryptic Leishmania donovani infection.

bioRxiv · Feb 3, 2023 · PreprintImmunology

Characterization of a new Leishmania major isolate for use in a controlled human infection model

H. Ashwin, J. Sadlova, B. Vojtkova, T. Becvar, P. Lypaczewski, E. Schwartz, E. Greensted, K. Van Bocxlaer, M. Pasin, K. Lipinski, V. Parkash, G. Matlashewski, A. Layton, C. Lacey, C. Jaffe, , P. Kaye

This paper isolates and characterizes a new Leishmania major strain for use in controlled human infection models to advance vaccine development.

bioRxiv · Aug 12, 2020Microbiology

A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis.

P. MacGregor, A. L. Gonzalez-Munoz, F. Jobe, M. C. Taylor, S. Rust, A. M. Sandercock, O. J. S. Macleod, K. Van Bocxlaer, A. F. Francisco, F. D'Hooge, A. Tiberghien, C. S. Barry, P. Howard, M. K. Higgins, T. Vaughan, , M. Carrington

This paper demonstrates that a single dose of an antibody-drug conjugate targeting the trypanosome receptor HpHbR completely cures a stage 1 mouse model of African trypanosomiasis.

bioRxiv · Feb 11, 2019Microbiology